The following is a summary of "Mental Health Status and Quality of Life is Not Improved in Amputees Following Targeted Muscle ...

The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

The primary endpoint of the study was analgesic efficacy, as measured by the Pain Numeric Rating Scale (NRS) Area Under the Curve for 2 to 48 hours (AUC 2-48) following dosing of cebranopadol vs ...

Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” ...

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.